Adage Capital Partners Gp, L.L.C. Praxis Precision Medicines, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.71 $738,944 - $1.45 Million	849,362 Added 10.71%	8,780,000 $15 Million
Q2 2023 Aug 14, 2023	BUY	$0.83 - $1.18 $4.99 Million - $7.09 Million	6,008,376 Added 312.57%	7,930,638 $9.12 Million
Q1 2023 May 15, 2023	SELL	$0.8 - $4.98 $267,023 - $1.66 Million	-333,779 Reduced 14.79%	1,922,262 $1.56 Million
Q3 2022 Nov 14, 2022	BUY	$2.5 - $37.95 $1.25 Million - $19 Million	500,000 Added 28.47%	2,256,041 $5.12 Million
Q2 2022 Aug 15, 2022	BUY	$1.75 - $11.34 $1.69 Million - $10.9 Million	963,960 Added 121.7%	1,756,041 $4.3 Million
Q1 2022 May 16, 2022	BUY	$10.21 - $20.29 $1.02 Million - $2.03 Million	100,000 Added 14.45%	792,081 $8.09 Million
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $1.34 Million - $1.84 Million	80,000 Added 13.07%	692,081 $13.6 Million
Q3 2021 Nov 15, 2021	BUY	$13.15 - $22.56 $328,750 - $564,000	25,000 Added 4.26%	612,081 $11.3 Million
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $3.2 Million - $5.78 Million	175,000 Added 42.47%	587,081 $10.7 Million
Q4 2020 Feb 16, 2021	BUY	$27.25 - $55.82 $11.2 Million - $23 Million	412,081 New	412,081 $22.7 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.26B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.